IL5 and pneumonia: Blood eosinophils in COPD patients should be detected for therapeutic choices: to select patients to be treated with combination of ICS/bronchodilators is needed to reduce the risk of pneumonia in patients without an eosinophilic inflammation, and to evaluate possible therapies with monoclonal antibodies against IL-5 or its receptor, decreasing T2 inflammation.